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Abstract Familial hypobetalipoproteinemia (FHBL) is a
genetically heterogeneous condition characterized by very
low apolipoprotein B (apoB) concentrations in plasma and/
or low levels of LDL-cholesterol (LDL-C) with a propensity
to developing fatty liver. In a minority of cases, truncation-
specifying mutations of the apoB gene (
 
APOB
 
) are etiologic,
but the genetic basis of most cases is unknown. We previ-
ously reported linkage of FHBL to a 10 cM region on
3p21.1-22 in one kindred. The objectives of the current
study were to identify other FHBL families with linkage to
3p and to narrow the FHBL susceptibility region on 3p. Six
additional FHBL kindreds unlinked to the 
 
APOB
 
 region on
chromosome 2 were genotyped with polymorphic markers
spanning a region of approximately 13 cM on chromosome
3.  Quantitative linkage analyses indicated that the FHBL
in these families was linked to 3p21.1-22. Haplotype analy-
sis identified several meiotic crossover events, allowing us
to narrow the critical region from 10 cM to 2.0 cM, between
markers D3S2407 and D3S1767.
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Familial hypobetalipoproteinemia (FHBL) is a disor-
der of lipoprotein metabolism characterized by extremely
low levels of LDL-cholesterol (LDL-C) and/or apolipo-
protein B (apoB), segregating as an autosomal dominant
trait (1–3). Mutations of the apoB gene (
 
APOB
 
) on chro-
mosome 2p23-24 are etiologic for FHBL. These mutations
result in a variety of truncated forms of apoB protein that
are designated according to a centile nomenclature (4).
The normal forms in plasma are apoB-100 consisting of
4,536 amino acids, and apoB-48, a product of apoB
mRNA editing that is 2,152 amino acids or 48% of the
full-length protein. In humans, apoB-100 is secreted
by the liver in VLDL particles and apoB-48 is secreted by
the small intestine in chylomicrons (2). Approximately
35 different truncations ranging from apoB-2 to apoB-89
 
have been described. Those longer than apoB-26 are
usually detectable in plasma, whereas shorter forms, al-
though secreted by liver and intestine, are not (5). Trun-
cation-producing mutations of 
 
APOB
 
 are found only in a
small minority of kindreds with FHBL (6–8), and the ge-
netic etiologies are not well understood in the over-
whelming majority of cases (7). However, it is clear that
FHBL is genetically heterogeneous (9–12). Fazio et al.
(13) and Pulai et al. (10) reported on 2 FHBL families
in which linkage to the apoB gene was ruled out. We re-
ported linkage of FHBL to a 10 cM region of 3p21.1-22
in one of those families, the F-family (11), suggesting
that a FHBL susceptibility gene may reside at that
location.
As part of an ongoing investigation seeking to discover
the genetic etiologies of FHBL, we have been ascertaining
and studying families with low plasma concentration of
LDL-C and apoB. We analyzed 21 hitherto unreported
kindreds with FHBL in which no unusual truncated forms
of apoB were present in plasma. Initially, we had sought
linkage to chromosome 2p (the well-known locus at or
near 
 
APOB
 
) by genotyping in the appropriate regions and
performing linkage analysis (Pin et al., unpublished ob-
servations). Quantitative trait loci (QTL) analysis indi-
cated that 7 of the 21 pedigrees were not linked to the
apoB region. These families were then genotyped with
markers mapped to 3p21.1-22. Quantitative linkage analy-
sis indicated that six of these pedigrees were linked to this
region, confirming and extending our original observa-
tion (11). To further narrow the susceptibility locus, we
performed haplotype analysis in one of the pedigrees with
crossovers in the critical region. These analyses implicated
a 2 cM region on 3p that may harbor a genetic susceptibil-
ity locus for FHBL.
 
Abbreviations: apoA-I, apolipoprotein A-I; apoB, apolipoprotein B;
BMI, body mass index; FHBL, familial hypobetalipoproteinemia; QTL,
quantitative trait loci.
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MATERIALS AND METHODS
 
Pedigrees
 
Ascertainment of potential probands with FHBL occurred by
screening volunteer populations in the metropolitan areas of St.
Louis, MO, for individuals with total plasma cholesterol levels
below 150 mg/dl. Probands provided information on their own
health status and on the structure of their kindred. Members of
21 pedigrees were invited to participate based on the presence
of two or more affected individuals in two or more generations,
the absence of truncated forms of apoB in plasma on immuno-
blotting (14), the absence of diabetes mellitus, thyroid, liver, and
kidney diseases, and a willingness to participate. None of the
participants was taking medications known to affect lipid metab-
olism. The Human Studies Committee of the Washington Uni-
versity Medical Center approved all protocols and informed con-
sent procedures.
Initially, the 21 families were genotyped for seven markers in
the apoB region on chromosome 2. Linkage analysis indicated
that seven of these pedigrees were not linked to the apoB gene (Pin
et al., unpublished observations). These families were then geno-
typed using ten chromosome 3 polymorphic tetra-, tri-, or di-nucle-
otide markers in a 13 cM region around marker D3S3678, the area
of maximum linkage previously identified in the F-kindred (11).
Marker order was obtained from the Marshfield Medical Research
Foundation’s Web site (http://www.marshfieldclinic.org/research/
genetics/) (15). Preliminary analysis indicated that one family
was not linked to chromosome 3 and was dropped from further
consideration.
Fig. 1. Familial hypobetalipoproteinemia (FHBL) kindreds, showing haplotypes consisting of 10 markers on chromosome 3p in pedigrees
2, 3, 7, 9, and 50. Pedigree 4 haplotypes include two additional markers. ApoB levels are given above the haplotype symbols. Solid symbols
denote subjects with apoB levels in the lower 5% for age and sex. Question marks denote borderline or unknown apoB levels. The black
bars represent purported haplotypes segregating with affected FHBL subjects.
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Fig. 1. (Contined)
 
Laboratory procedures
 
Lipid and apolipoprotein analyses.
 
Bloods were drawn after 12 h
of fasting into EDTA tubes (1 mg/ml). Plasmas were analyzed
for total TGs and cholesterol using enzymatic methods (Wako
Cholesterol and TG kits) in the Core Laboratory for Clinical
Studies, which is CDC-standardized and monitored. VLDL, LDL,
and HDL were isolated by ultracentrifugation and dextran sul-
fate precipitation (16), and their TG and cholesterol contents as-
sessed by enzymatic methods as above. The coefficients of varia-
tion of the lipid assays are 
 
,
 
3%. Total plasma apolipoprotein
(apo)A-I and apoB concentrations were determined by immuno-
nephelometry [coefficients of variation (CVS) of 7% and 8%]
(17). Aliquots of whole blood were frozen for DNA analysis.
 
Genotyping.
 
Genomic DNA was extracted from the peripheral
blood leukocytes using the Gentra Puregene
 
TM
 
 DNA extraction
kit. PCR amplifications were carried out with 30 ng of genomic
DNA in a 15 ul reaction volume containing 3 pmol of each
primer, 0.9 U 
 
Taq
 
 DNA polymerase (PE Applied Biosystem), 200
uM dNTPs, 1.5 mM MgC1
 
2
 
, and PCR buffer (10 mM Tris-HC1,
pH 8.3; 50 mM KC1; 1% Triton-X-100). The thermal cycling con-
ditions were as follows: initial denaturation for 5 min at 95
 
8
 
C, fol-
lowed by 30 cycles of 94
 
8
 
C for 30 s, 55
 
8
 
C for 45 s, 72
 
8
 
C for 30 s,
and a terminal extension for 30 min at 72
 
8
 
C in a thermocycler
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(PTC-200, MJ Research). The PCR products were analyzed using
ABI 377 automated DNA sequencer (PE Applied Biosystem)
with the ABI PRISM GeneScan Analysis Software (V2.1.2 and 3.1
PE Applied Biosystem) and ABI PRISM Genotyper version 2.0
(PE Applied Biosystem). Allele sizes were determined using
GENESCAN
 
TM
 
 -500 Rox as a size standard (PE Applied Biosys-
tem). Primer sequence information was obtained from the
Genome Database (http://www.gdb.org/), GenBank (http://
www.ncbi.nlm.nih.gov/Genbank/), and the Genethon data-
base (http://www.genethon.fr/genethon_en.html).  Genotypes
were checked for typing errors with the GenoCheck program
(18, 19).
 
Linkage analyses
 
Linkage analyses were performed using the computer pro-
grams SOLAR release 1.6.6 (20) and Loki 2.3 (21). Neither spec-
ifies a putative genetic model for the trait (such as dominant, ad-
ditive, or recessive) with an accompanying penetrance function.
However, the mathematical underpinnings of these two software
packages are quite different. SOLAR conducts two point and
multipoint linkage analysis within the variance component frame-
work. Briefly, the goal of variance component analyses is to parti-
tion the observed variation of the trait into a sum of variances,
each of which is genetic or environmental in nature. We pro-
ceeded by first comparing a polygenic model to a sporadic
model (no genetic components). Logarithm of odds (LOD)
scores were then computed to test the null hypothesis that the
additive genetic variance due to a potential QTL equals 0, by
comparing the maximum likelihoods between a model that as-
sumes the presence of a trait-related QTL and an unlinked poly-
genic background, to a model without the susceptibility QTL.
SOLAR assumes a normal distribution of the trait phenotype.
Fig. 1. (Continued)
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Accordingly, all analyses were performed on the square root of
the apoB level.
Loki performs multipoint linkage analysis on quantitative
traits using oligogenic models (models with multiple putative
QTLs) without assigning a fixed number of potential QTLs. The
number of QTLs and their chromosomal locations are estimated
using a sampling method called reversible jump Markov chain
Monte Carlo (MCMC) (21). To determine linkage, a statistic
known as the Bayes Factor (22) or L-Score is computed as fol-
lows: For each sampling iteration (300,000 iterations were used
for each analyses), the prior probability of finding a QTL linked
to a 1 cM bin is 1/t where t is the total map length of the ge-
nome (approximately 33 Morgans). If, for a particular iteration,
there are n QTLs in the model, the prior probability, p, of at
least one QTL located in the bin is 1 
 
2
 
 (1 
 
2
 
 1/t)
 
n
 
. The posterior
probability, q, is 1 or 0 depending on whether at least one QTL is
located in the 1 cM bin. The Bayes Factor (L-score) for each bin
is estimated by averaging q/p over all iterations. Regions that
have a high probability of containing a QTL will have consider-
ably elevated L-scores compared with surrounding regions. The
Bayes Factors cannot be quantified in terms of a LOD score, but
guidelines for estimating the importance of the Bayes factor are
given by Kass and Raftery (22). Scores in the range of 3 to 20 are
considered positive signals, 20 to 150 are considered strong, and
over 150 very strong. Loki has successfully identified two known
genes in an Alzheimer data set (23) and the trait genes in simu-
lated complex traits (21, 24). Loki was initially executed 20 –30
times, with different starting seeds, on all seven pedigrees to be
sure about the consistency of the results. We then ran Loki multi-
ple times with six pedigrees, leaving out one pedigree each time,
to see if results would be influenced by the omission of any one
pedigree. One pedigree significantly lowered the L-score. This
pedigree was quite small with only four genotyped family mem-
bers. Consequently, this pedigree was omitted from any further
analyses. Sex and age were included as covariates in all analyses.
To identify crossover events, haplotypes were constructed
using the computer program Simwalk (v. 2.6) based on MCMC
and simulated annealing methods to compute the most likely
haplotypes (25).
 
RESULTS
The six families included in our quantitative analysis
study consisted of 57 genotyped individuals (
 
Fig. 1
 
, 
 
Table
1
 
). For purposes of haplotype analysis (see below), pedi-
 
TABLE 1. Clinical characteristics of the FHBL families
 
Family Status Values Age BMI
Total
Cholesterol TG LDL ApoB HDL ApoA-I
 
years kg
 
/
 
m
 
2
 
mg/dl
 
2 Affected Mean 19.4 20.6 130.4 66.3 67.0 52.4 52.3 128.8
n 
 
5
 
 4 Minimum 6.0 16.5 118.5 59.0 51.5 49.5 57.5 116.0
Maximum 34.5 24.6 139.0 71.0 75.5 56.0 58.0 145.5
Normal Mean 50.0 30.1 168.8 123.5 100.5 81.5 45.8 134.3
n 
 
5
 
 2 Minimum 37.5 24.2 141.5 121.0 81.0 67.5 36.0 111.0
Maximum 62.5 36.0 196.0 126.0 120.0 95.5 55.5 157.5
3 Affected Mean 28.2 21.2 139.9 55.2 69.4 53.8 61.22 140.8
n 
 
5
 
 3 Minimum 9.0 20.9 137.3 44.7 66.3 51.0 60.5 133.0
Maximum 38.0 21.5 143.5 69.0 73.0 55.5 62.7 149.5
Normal Mean 47.8 21.0 197.1 72.3 120.8 89.8 62.6 151.3
n 
 
5
 
 6 Minimum 10.0 14.6 176.0 50.0 110.5 79.5 46.5 128.0
Maximum 72.0 25.8 231.0 117.0 142.0 97.0 80.5 182.5
4 Affected Mean 46.7 23.2 133.7 76.4 75.5 59.3 44.0 121.1
n 
 
5
 
 5 Minimum 33.0 18.8 122.0 48.0 64.0 55.0 38.0 106.0
Maximum 63.0 27.0 167.0 92.0 96.7 65.0 52.0 146.7
Normal Mean 44.2 25.0 186.8 176.8 114.4 102.7 37.5 110.2
n 
 
5
 
 9 Minimum 14.0 19.8 134.0 67.0 80.0 73.0 23.5 1.0
Maximum 66.0 32.3 255.0 341.0 175.0 143.0 49.0 149.0
7 Affected Mean 32.3 22.0 114.0 47.6 58.4 48.4 48.3 126.6
n 
 
5
 
 4 Minimum 18.0 20.0 98.5 31.0 47.5 35.0 44.5 117.0
Maximum 47.0 25.1 130.0 61.0 73.5 63.0 52.5 132.0
Normal Mean 62.3 29.4 200.8 85.5 141.8 111.6 45.3 133.3
n 
 
5
 
 2 Minimum 48.5 26.6 192.5 69.0 138.5 110.0 42.5 118.0
Maximum 76.0 32.2 209.0 102.0 145.0 113.5 48.0 148.5
9 Affected Mean 53.3 24.2 136.7 77.0 73.0 64.0 48.0 145.0
n 
 
5
 
 3 Minimum 23.0 22.5 132.0 45.0 67.0 57.0 37.0 129.0
Maximum 90.0 26.1 140.0 105.0 80.0 71.0 56.0 154.0
Normal Mean 50.0 29.7 157.0 126.0 100.0 88.0 32.0 130.0
n 
 
5
 
 1 Minimum 50.0 29.7 157.0 126.0 100.0 88.0 32.0 130.0
Maximum 50.0 29.7 157.0 126.0 100.0 88.0 32.0 130.0
50 Affected Mean 43.7 24.7 102.0 50.7 32.8 27.8 59.2 150.3
n 
 
5
 
 6 Minimum 11.0 18.2 66.0 10.0 20.0 15.0 26.0 100.0
Maximum 82.0 30.7 139.0 89.0 45.0 41.0 82.0 215.0
Normal Mean 31.3 24.7 191.9 98.1 119.4 95.7 53.0 148.6
n 
 
5
 
 7 Minimum 9.0 18.1 124.0 27.0 70.0 57.0 44.0 121.0
Maximum 63.0 29.8 272.0 161.0 185.0 143.0 62.0 181.0
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gree members with apoB levels 
 
<
 
5th percentile for age
and sex (17) were considered affected. The FHBL affecta-
tion status of five genotyped individuals was declared
unknown either because of borderline apoB levels or dis-
parate apoB, and/or LDL-C concentrations on repeat de-
terminations, probably due to biologic variation. (In gen-
eral, the precision of apoB and LDL-C measurements is
high. See the Materials and Methods section.)
 
Linkage analysis
 
Two-point and multipoint point analyses were con-
ducted using 10 markers spanning 13 cM on chromosome
3 in the region of interest (
 
Table 2
 
). For both analyses the
phenotype was defined to be the square root of the apoB
level to reduce kurtosis. Because Loki is a MCMC method,
analyses were repeated multiple times, each with different
starting values. Positive L-scores were seen at approximately
69 cM, between D3S3678 and D3S3582, over all replicate
runs. The average L-score for 20 runs was 30.4 (SD 
 
5
 
 3.1),
that is, the ratio between observed and expected (under
the null hypothesis of no linkage) number of QTLs in a
particular bin was, on average, over 30, considered to be a
strong signal (22). 
 
Figure 2
 
 displays a representative histo-
gram of map position versus L-score (Bayes Factor).
Results from the 2-point analysis using SOLAR were con-
sistent with the Loki results. The LOD score obtained when
comparing a polygenic model with a sporadic model (no
genetic component) was highly significant (
 
P
 
 
 
<
 
 0.0004), in-
dicating the presence of genetic factors. Two-point linkage
analysis gave the strongest evidence for linkage to a chro-
mosome 3 QTL at marker D3S3678 located at 68.5 cM on
the Marshfield map where the LOD score was 2.9 (Table 2).
Multipoint linkage analysis with SOLAR yielded a maxi-
mum multipoint LOD score of 1.6 between markers
D3S3678 and D3S3582 (
 
Fig. 3
 
). The QTL and residual her-
itabilities at this location were 0.6 and 0.3, suggesting that
additional genetic factors may contribute to apoB variation.
 
Haplotype analysis
 
Haplotypes spanning approximately 13.4 cM on chromo-
some 3 were constructed using 10 polymorphic DNA mark-
ers (Fig. 4). Crossovers were found in family 4 (individuals
3, 7, and 13) that helped to define the borders of the criti-
cal region (
 
Fig. 4
 
). The telomeric border of the critical re-
gion was defined by a crossover in the mother of unaffected
subject 13 of family 4 between D3S2407 and D3S3678. The
centromeric border was defined by a recombination event
in the parent of affected individual 7 between D3S3582 and
D3S1588 within a span of 2.67 cM. Additional markers were
subsequently genotyped in this region for family 4, result-
ing in narrowing the region to 2 cM between D3S2407 and
D3S1767, a physical distance of approximately 6 million
base pairs (Fig. 4). Unaffected subject 9, 40.5 years of age,
had an apoB level of 85.5, placing him in the lower 25th
percentile for his age and sex, also carried the affected hap-
lotype, indicating unknown environmental or additional
genetic factors influencing systemic apoB level. Thus, we
have considerably narrowed the size of the critical region
from our previous analysis (11).
DISCUSSION
We had previously reported that chromosome 3 con-
tained a susceptibility gene for FHBL based on linkage
analysis in a large multigenerational family. Twenty-one
 
TABLE 2. Two-point solar results
 
Marker Location
LOD 
Scores
QTL
 
a
 
h
 
2
 
Residual
 
b
 
h
 
2
 
D3S1768 61.52 0.40 0.30 0.63
D3S3527 63.12 0.12 0.20 0.73
D3S3521 63.12 0.22 0.22 0.71
D3S2407 67.94 0.12 0.15 0.78
D3S3678 68.47 2.93 0.86 0.00
D3S3582 69.19 0.74 0.36 0.53
D3S1588 70.61 0.53 0.32 0.61
D3S1289 71.41 0.66 0.37 0.53
D3S1613 72.21 0.15 0.29 0.57
D3S3717 74.35 0.47 0.35 0.53
 
a
 
Variance due to the QTL.
 
b
 
Variance due to residual polygenes.
Fig. 2. Histogram of map position (cM) versus
L-score. The tick marks at the top of the graph indi-
cate the location of the markers used in the analysis.
See Table 2 for marker names and locations.
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new kindreds with FHBL were identified as suitable for
further study, based on our selection criteria as described.
Seven of these gave no evidence of linkage to the 
 
APOB
 
 re-
gion on chromosome 2. We hypothesized that some of
these families would be linked to chromosome 3. Signifi-
cant evidence for QTL activity was detected on chromo-
some 3 for six of these families using two different QTL
approaches. This confirms our previous finding of a sus-
ceptibility locus for FHBL at 3p21.1-22 (11).
Further analyses identified crossovers in family 4, per-
mitting the narrowing of the critical region. Individual 13
in family 4 defined the telomeric border of the region
near D3S2407. This was consistent with our previous re-
port (11) in which individual 314 of the F-family had a
crossover between D3S3521 and D3S2407, confirming
that the telomeric border of the critical region was in the
vicinity of D3S2407. Individual 7 of family 4 defined the
centromeric border near D3S3582. Thus, we were able to
narrow the region from 10 cM to 2 cM.
A recent paper by Ko et al. (26) further supports the
possibility of a susceptibility locus for FHBL with human
chromosome 3. Using F2 and N2 (backcrossed) offspring
of two mice strains that are high and low human apoB
producers, they identified two quantitative trait loci as the
major regulators of the protein levels. One locus was local-
ized to mouse chromosome 6 and the other to chromo-
some 4. The mouse chromosome 6 region is syntenic with
human chromosome 3p.
The importance of finding the genetic causes of low cho-
lesterol is many fold. First, low cholesterol levels confer lon-
gevity and protection against coronary heart disease (27–
29). Second, several reports have shown that subjects with
FHBL may have increased susceptibility for developing fatty
livers (30–36), including subjects from the F-family where
no apoB defects are apparent and linkage to 3p21.1-22 has
been reported (30). The predisposition to fatty liver ap-
pears to be due to the limited capacities of the liver in these
individuals to export TGs in VLDL particles, as apoB-100
production rates are reduced to about 30% of normal rates
(14, 37, 38). Similarly, there are elevated levels of TGs in liv-
ers of engineered mice bearing two different truncation-
producing mutations of 
 
APOB
 
 (39, 40). In these mice, the
limitation on hepatic TG export in VLDL particles also
seems to be responsible for the fatty livers. The fatty liver of
FHBL differs from the fatty livers seen in obesity and diabe-
tes mellitus, which appear to be due to overproduction of
TGs in liver (41). It is our hope that identifying the muta-
tions causing FHBL will provide new insights into the as-
sembly and secretion of VLDL particles, i.e., the hepatic
TG-exporting system, and the complexities of fatty liver. It
may also provide new opportunities in the prevention and
treatment of coronary heart disease.
Fig. 3. SOLAR multipoint logarithm of odds
(LOD) scores. The tick marks at the top of the graph
indicate the location of the markers used in the analy-
sis. See Table 2 for marker names and locations.
Fig. 4. Map of FHBL region taken from Marshfield integrated
map of Santa Cruz physical map (*based on December 12, 2000,
freeze). The recombination events occurred between polymorphic
markers D3S2407 and D3S3685, and D3S3582 and D3S1767. The
critical region is between D3S2407 and D3S1767.
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